111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in human thyroid tumours

Forssell‐Aronsson, Eva; Nilsson, Ove; Benjegård, S. A.; Kölby, Lars; Bernhardt, Peter; Mölne, Johan; Hashemi, H.; Wängberg, Bo; Tisell, Lars‐Erik; Ahlman, Håkan

doi:10.1097/00006231-200006000-00100

Cited by 32 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The origin of GOT2 was a tumor biopsy from a patient with MTC harvested at surgery. Many MTCs overexpress SSTR and CCK2/gastrin receptors (24)(25)(26)41). Somatostatin receptor scintigraphy can be used for localization of MTC prior to surgery (42), and therapy using radiolabeled somatostatin analogues have been suggested for patients with high SSTR expression and nonresectable tumor (41).…”

Section: Discussionmentioning

confidence: 99%

“…Many MTCs overexpress SSTR and CCK2/gastrin receptors (24)(25)(26)41). Somatostatin receptor scintigraphy can be used for localization of MTC prior to surgery (42), and therapy using radiolabeled somatostatin analogues have been suggested for patients with high SSTR expression and nonresectable tumor (41). Furthermore, many radiolabeled CCK2 and gastrin analogues are produced and tested for binding specificity in order to find new radiopharmaceuticals useful for localization of tumors expressing CCK2/gastrin receptors (12,31,32).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

et al. 2011

View full text Add to dashboard Cite

Abstract.To be able to evaluate new radiopharmaceuticals and optimize diagnostic and therapeutic procedures, relevant animal models are required. The aim of this study was to evaluate the medullary thyroid carcinoma GOT2 animal model by analyzing the biodistribution of 177 Lu-octreotate and 111 In-minigastrin (MG0). BALB/c nude mice, subcutaneously transplanted with GOT2, were intravenously injected with either 177 Lu-octreotate or 111 In-MG0, with or without excess of unlabeled human minigastrin simultaneously with 111 In-MG0. Animals were sacrificed 1-7 days after injection in the 177 Lu-octreotate study and 1 h after injection of 111 In-MG0. The activity concentrations in organs and tissues were determined and mean absorbed doses from 177 Lu were calculated. There was a specific tumor uptake of either 177 Lu-octreotate or 111 In-MG0. 177 Lu-octreotate samples showed high activity concentrations in tissues expressing somatostatin receptors (SSTR). For both radiopharmaceuticals the highest activity concentrations were found in the kidneys. Compared to results from similar studies in mice with another MTC cell line (TT) the biodistribution was favorable (higher tumor uptake) for the GOT2 model, while compared to other animal models expressing SSTR, the tumor uptake of 177 Lu-octreotate was modest. In conclusion, the GOT2 animal model is a valuable model for evaluation and optimization of diagnostic and therapeutic procedures using radiolabeled somatostatin, CCK2 and gastrin analogues prior to clinical studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

et al. 2011

View full text Add to dashboard Cite

show abstract

“…When octreotide, a synthetic analogue of somatostatin with a considerably longer half-life, is combined with a radioactive isotope such as indium-111 (emits gamma photons of energies 172 and 245 keV and Auger electrons with tissue penetration 0.02 -500 mm), peptide receptor imaging can be performed to visualise tumours with a high concentration of somatostatin receptors (Wilson et al, 1998). Multiple somatostatin receptor subtypes are known to be present in medullary thyroid cancer, but actually the majority of thyroid tumours regularly express most, if not all, of the somatostatin receptor subtypes (Forssell-Aronsson et al, 2000). Studies indicate the existence of two groups of receptors -sstr1/sstr4 with virtually no or very lowaffinity and sstr2/sstr3/sstr5 with intermediate to high affinity for the somatostatin analogues, such as octreotide and lanreotide (Bruns et al, 1995).…”

mentioning

confidence: 99%

Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid

2003

View full text Add to dashboard Cite

Treatment of differentiated thyroid cancer is a success of modern medicine with the use of radioiodine ( 131 I). However, a significant proportion of thyroid cancers may be non-iodine avid. Thyroid tumours are known to express somatostatin receptors. Octreotide, an analogue of somatostatin, can be combined with a radioactive isotope, such as 111 In-DTPA 0 to visualise tumours with high concentrations of somatostatin receptors. We assessed 18 patients with histologically proven metastatic or locally recurrent noniodine avid thyroid carcinoma to determine the usefulness of 111 In-DTPA 0 octreotide scintigraphy compared to conventional radiology in diagnosing sites of metastasis. The diagnosis of metastatic disease was made using conventional radiology and all had prospective scintigraphy using 111 In-DTPA 0 octreotide. Of the 18 patients, 14 had octreotide-positive scans. In eight, the octreotide scans identified the same sites of metastases as conventional radiology, that is, were concordant. In nine patients, conventional radiology showed more extensive disease than revealed on the octreotide scans. In one patient with widespread bone metastases, octreotide gave a more detailed assessment of metastatic disease than conventional radiology. These data indicate that 111 In-DTPA 0 octreotide imaging for patients with non-iodine avid carcinoma of the thyroid may be a useful diagnostic and staging tool. One patient with Hurthle cell carcinoma metastatic to bone and a positive octreotide scan has been treated with 90 yttrium-labelled octreotide.

show abstract

“…SSRT3 was found in 31% of cases, SSRT5 in 44%, and SSRT1 and SSRT4 were not detected in any of the samples. Forssell-Aronsson et al [59] have investigated tissue samples from 68 patients and have reported that all thyroid tumor types regularly express SSRT1, SSRT3, SSRT4 and SSRT5. Although SSRT2 is expressed in most medullary thyroid carcinomas, it is not detected in 60 February 28, 2010|Volume 2|Issue 2| WJR|www.wjgnet.com Tan EH et al .…”

Section: B Amentioning

confidence: 99%

Exploring new frontiers in molecular imaging: Emergence of⁶⁸Ga PET/CT

Tan

Goh²

2010

WJR

View full text Add to dashboard Cite

Since US Food and Drug Administration approval of 18-fluorodeoxyglucose as a positron tracer, and the development of hybrid positron emission tomography/ computed tomography machines, there has been a great increase in clinical application and progress in the field of nuclear molecular imaging. However, not underestimating the value of 18 F, there are known limitations in the use of this cyclotron-produced positron tracer. We hence turn our focus to an emerging positron tracer, 68 Ga, and examine the advantages, current clinical uses and potential future applications of this radioisotope. THE DEVELOPMENT OF POSITRON EMISSION TOMOGRAPHYPositron emission tomography (PET) imaging is essentially a story of a technique in wait of a technology. Since the discovery of positron emission in 1933 by Thibaud and Joliot et al, and the subsequent report of the coincident nature of emissions by Klemperer and Beringer, it has in effect taken close to half a century for the full realization of PET imaging in mainstream medical practice [1] . The history of PET development is a fascinating look into the technological advances in molecular medicine, and the account of Terry Jones provides fascinating reading [1] . The first use of positron tracers was likely performed in the 1940s using 11 CO in animal models [2] , with its first possible use in humans performed in the 1950s at the Hammersmith Hospital in London, United Kingdom using 15 O2 in studies of lung ventilation [3] . This was followed by increasing use of positron tracers in the physiological assessment of lung function, which resulted in the installation of the world's first hospital-based cyclotron in 1955. Subsequently, development shifted into myocardial perfusion [4] , cerebral perfusion [5][6][7] , and of course, glucose metabolism [8][9][10][11] . This development in positron tracers mirrored the progress in positron imaging. In the 1970s, Massachusetts General Hospital developed, what was then, the most advanced coincidence positron camera system, with a spatial resolution of approximately 1 cm [12] . This was followed by developments predominantly in single photon emission computed tomography (SPECT) with work done by Kuhl, Budinger and Gullberg, and in 1974, there were reports of the development of a dedicated single-plane positron emission transaxial tomograph, which was the precursor to the current PET systems.These developments explain the slow implementation of PET into clinical practice, as synchronous developments in both tracer and detector technology were reWorld Journal of Radiology W J R

show abstract

111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in human thyroid tumours

Cited by 32 publications

References 0 publications

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid

Exploring new frontiers in molecular imaging: Emergence of⁶⁸Ga PET/CT

Contact Info

Product

Resources

About

111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in human thyroid tumours

Cited by 32 publications

References 0 publications

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid

Exploring new frontiers in molecular imaging: Emergence of68Ga PET/CT

Contact Info

Product

Resources

About

Exploring new frontiers in molecular imaging: Emergence of⁶⁸Ga PET/CT